Condition: Geographic Atrophy Secondary to Age-related Macular Degeneration · Sponsor: Okuvision GmbH
Geographic atrophy (GA) is a progressive eye disease that causes the degeneration of the retinal cells, particularly in the macula, leading to vision loss. The goal of this pilot study is to evaluate the safety and the effectiveness of transcorneal electrical stimulation (TES) therapy with the OkuStim 2 System in patients with geographic atrophy (GA). Researchers will compare the effects of two different electrical stimuli with a placebo to see if the stimuli are safe and can slow down the progression of the disease. Participants will be randomly assigned to one of these three groups: * TES-treatment with a rectangular stimulus * TES-treatment with a repetitive ramp stimulus * Placebo (sham) treatment Participants will apply the therapy at home, once a week for 30 minutes each over a duration of 1 year.
This description comes directly from the study's public registry record.
Ruth Schippert, PhD · +49 7121 15935 · studies@okuvision.de
Always discuss trial participation with your own doctor first.
| Department of Ophthalmology, University Medical Center Hamburg-Eppendorf | Hamburg, Germany | Recruiting |
| Department of Ophthalmology, Ludwig-Maximilians-University Munich | München, Germany | Recruiting |
| Department of Ophthalmology, Klinikum Stuttgart | Stuttgart, Germany | Recruiting |
| Centre for Ophthalmology, University Hospital Tuebingen | Tübingen, Germany | Recruiting |
| Department of Ophthalmology, University Hospital Ulm | Ulm, Germany | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07531927